VolitionRx (NYSE-A:VNRX) has outlined its key achievements in 2022 as the organization transitions from a company solely focused on research and development to one with commercial operations.
Henderson, Nevada-based Volition is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.
In a business review, Volition president and CEO Cameron Reynolds said: "2022 was a phenomenal year for Volition. For over a decade we have sought to advance the science of epigenetics, develop and refine our technology to be - what we believe to be - the best-in-class in the diagnostics industry".
READ: VolitionRX ends Q3 with $16.4 million cash, moves from R&D to commercial cancer screening company
Volition's major achievements in 2022 include:
- Expanding access to the Nu.Q Vet Cancer Test on a worldwide basis;
- Achieving a CE mark for Nu.Q NETs;
- Launching its US clinical product development and regulatory programs;
- Developing its Nu.Q pipeline; and
- Scaling up its operations.
"Powered by Nu.Q, our Nucleosomics technology has the potential to play an important role in the fight to save lives and improve outcomes worldwide and we are thrilled that our Nu.Q Vet Cancer Test is now commercially available, with plans to commercialize Nu.Q NETs also well underway. We expect that 2023 will be another exciting year,” Reynolds concluded.
Contact the author at stephen.gunnion@proactiveinvestors.com